Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II exploratory multicohort study of cadonilimab combined with ivonescimab in recurrent ovarian cancer
CTR20242621Phase 2Active
- Sponsor
- CTTQ-Akeso
- Start
- Nov 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab, ivonescimab in ovarian cancer, sponsored by CTTQ-Akeso. Started Nov 2024; status: active.
02
Drugs
cadonilimabivonescimab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on CTR20242621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242621.